Compare INGR & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGR | IBRX |
|---|---|---|
| Founded | 1906 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 7.5B |
| IPO Year | 1997 | 2015 |
| Metric | INGR | IBRX |
|---|---|---|
| Price | $104.82 | $7.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $128.57 | $12.57 |
| AVG Volume (30 Days) | 634.8K | ★ 8.6M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | 15.14 | ★ 38.71 |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $7,219,000,000.00 | $113,288,000.00 |
| Revenue This Year | $3.86 | $88.59 |
| Revenue Next Year | $2.95 | $131.15 |
| P/E Ratio | $26.23 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $94.44 | $1.95 |
| 52 Week High | $130.48 | $12.43 |
| Indicator | INGR | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 49.30 |
| Support Level | $101.51 | $6.68 |
| Resistance Level | $105.06 | $8.46 |
| Average True Range (ATR) | 2.14 | 0.36 |
| MACD | 0.25 | 0.06 |
| Stochastic Oscillator | 76.87 | 65.13 |
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.